These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 27929269)
1. Aripiprazole vs. Placebo or Haloperidol for Schizophrenia. Zehtabchi S Am Fam Physician; 2016 Dec; 94(11):877-878. PubMed ID: 27929269 [No Abstract] [Full Text] [Related]
2. Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. Parabiaghi A; Tettamanti M; D'Avanzo B; Barbato A; Acta Psychiatr Scand; 2016 Jan; 133(1):63-75. PubMed ID: 26252780 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Kasper S; Lerman MN; McQuade RD; Saha A; Carson WH; Ali M; Archibald D; Ingenito G; Marcus R; Pigott T Int J Neuropsychopharmacol; 2003 Dec; 6(4):325-37. PubMed ID: 14609439 [TBL] [Abstract][Full Text] [Related]
4. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Kane JM; Crandall DT; Marcus RN; Eudicone J; Pikalov A; Carson WH; Swyzen W Schizophr Res; 2007 Sep; 95(1-3):143-50. PubMed ID: 17644313 [TBL] [Abstract][Full Text] [Related]
5. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. Barbui C; Accordini S; Nosè M; Stroup S; Purgato M; Girlanda F; Esposito E; Veronese A; Tansella M; Cipriani A; J Clin Psychopharmacol; 2011 Jun; 31(3):266-73. PubMed ID: 21508849 [TBL] [Abstract][Full Text] [Related]
6. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. Cipriani A; Accordini S; Nosè M; Purgato M; Girlanda F; Tansella M; Barbui C J Clin Psychopharmacol; 2013 Aug; 33(4):533-7. PubMed ID: 23775051 [TBL] [Abstract][Full Text] [Related]
7. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426 [TBL] [Abstract][Full Text] [Related]
8. Aripiprazole: new drug. Just another neuroleptic. Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069 [TBL] [Abstract][Full Text] [Related]
9. Aripiprazole and haloperidol: beneficial combination antipsychotic therapy for a schizophrenic patient. Kuo J; Hwu HG Clin Neuropharmacol; 2008; 31(3):173-5. PubMed ID: 18520984 [TBL] [Abstract][Full Text] [Related]
10. Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. Docherty JP; Baker RA; Eudicone J; Mathew S; Marcus RN; McQuade RD; Mankoski R Schizophr Res; 2010 Jul; 120(1-3):199-203. PubMed ID: 20547037 [TBL] [Abstract][Full Text] [Related]
11. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Andrezina R; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; McQuade RD Curr Med Res Opin; 2006 Nov; 22(11):2209-19. PubMed ID: 17076982 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. Kane JM; Barnes TR; Correll CU; Sachs G; Buckley P; Eudicone J; McQuade R; Tran QV; Pikalov A; Assunção-Talbott S J Psychopharmacol; 2010 Jul; 24(7):1019-29. PubMed ID: 20008446 [TBL] [Abstract][Full Text] [Related]
13. Aripiprazole: novelty, adherence and understatement. Fear C Int J Neuropsychopharmacol; 2005 Mar; 8(1):131. PubMed ID: 15469664 [No Abstract] [Full Text] [Related]
14. Aripiprazole and haloperidol: a clinically relevant interaction with a dopamine antagonist and partial agonist. Burke MJ; Lincoln J Ann Clin Psychiatry; 2006; 18(2):129-30. PubMed ID: 16754419 [No Abstract] [Full Text] [Related]
15. [Clinical observations with aripiprazole in schizophrenia]. Gaszner P Neuropsychopharmacol Hung; 2006 Mar; 8(1):29-32. PubMed ID: 16841563 [TBL] [Abstract][Full Text] [Related]
16. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Wright P; Lindborg SR; Birkett M; Meehan K; Jones B; Alaka K; Ferchland-Howe I; Pickard A; Taylor CC; Roth J; Battaglia J; Bitter I; Chouinard G; Morris PL; Breier A Can J Psychiatry; 2003 Dec; 48(11):716-21. PubMed ID: 14733451 [TBL] [Abstract][Full Text] [Related]
17. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Naber D; Lambert M Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1213-9. PubMed ID: 15588748 [TBL] [Abstract][Full Text] [Related]
18. The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia. Parabiaghi A; D'Avanzo B; Tettamanti M; Barbato A; Contemp Clin Trials; 2011 Sep; 32(5):675-84. PubMed ID: 21554991 [TBL] [Abstract][Full Text] [Related]
19. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Citrome L Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020 [TBL] [Abstract][Full Text] [Related]
20. Haloperidol vs. Low-Potency Antipsychotic Drugs for Schizophrenia. Bryan TL Am J Nurs; 2015 Jul; 115(7):21. PubMed ID: 26110946 [No Abstract] [Full Text] [Related] [Next] [New Search]